Up to 40% of patients with symptoms suspicious of gastroesophageal reflux disease (GERD)
do not respond completely to proton pump inhibitor (PPI) therapy. The term “refractory …

Helicobacter pylori is the first formally recognized bacterial carcinogen and is one of the
most successful human pathogens, as over half of the world's population is colonized with …

Background & Aims For decades, proton pump inhibitors (PPIs) have been the mainstay of
treatment for erosive esophagitis. The potassium-competitive acid blocker vonoprazan …

Advances in bioinspired design principles and nanomaterials have led to tremendous
progress in autonomously moving synthetic nano/micromotors with diverse functionalities in …

Proton‐pump inhibitor failure has become a common clinical dilemma in gastrointestinal
clinics and has been increasingly encountered at the primary care level as well. Underlying …

Barrett's esophagus is associated with reflux disease and substantially increases the risk of
esophageal adenocarcinoma. The authors undertook a systematic review and meta …

Objectives: To ascertain the prevalence of Helicobacter pylori in patients with gastro-
oesophageal reflux disease and its association with the disease. Design: Systematic review …

BACKGROUND: Gastroesophageal reflux disease (GERD) is the most prevalent acid‐
related disorder in Canada and is associated with significant impairment of health‐related …

Gastric acid secretion is a complex phenomenon under nervous and hormonal influence.
The stimulation of proton pump (H+, K+-ATPase) in the parietal cell represents the final step …

OBJECTIVES: Some studies suggest that eradication ofHelicobacter pylori (Hp) might
increase the risk of gastroesophageal reflux disease (GERD) in a portion of patients. We …